ZAK Zürich pp 196-203 | Cite as

Recent Developments in the Field of Muscle Relaxants: Clinical Pharmacology and Pharmacokinetics

  • S. Agoston
  • J. Swen
  • F. J. Richardson
  • O. M. Rashkovsky
  • D. E. F. Newton
  • A. Bencini
  • J. M. Ket
Conference paper
Part of the Anaesthesiologie und Intensivmedizin / Anaesthesiology and Intensive Care Medicine book series (A+I, volume 188)


The search for the “ideal” neuromuscular blocking agent — a nondepolarizing drug with a time course of action similar to that of suxamethonium but without its well-known side effects — has been continuing for more than 20 years. In 1975, Savarese and Kitz [18], describing the desired clinical requisites for new neuromuscular blocking agents, proposed three classes: ultra-short-acting agents (similar to suxamethonium), drugs with an intermediate duration of action (i.e., between suxamethonium and pancuronium), and long-acting agents. New drugs should be free of side effects and belong to the category of nondepolarizing neuromuscular blocking agents in order to avoid the unwanted effects inherent in drugs with a depolarzing mode of action. An ultra-short-acting competitive agent has still not been discovered. During the last 2 years, however, three new nondepolarizing compounds have either been introduced into clinical practice or reached the stage of clinical investigation. These are vecuronium bromide (Org NC 45) and atracurium besilate, which both have a short to intermediate duration of action, and pipecuronium bromide, a drug with a long duration of action.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Basta et al (1982) Anesth Anaig 61:723Google Scholar
  2. 2.
    Basta et al (1983) Br J Anaesth 55:1055Google Scholar
  3. 3.
    Beneini A (1983) Clinical pharmacokinetics of vecuronium bromied. In: Agoston S (ed) Clinical experiences with norcuron. Excerpta Medica, Amsterdam (Excerpta Medica Current Clinical Practice Series, vol 6, pp 25–37Google Scholar
  4. 4.
    Bowman WE, Norman J (eds) (1980) Symposium on Org NC 45. Br J Anaesth [Suppl] 52Google Scholar
  5. 5.
    Chappie DJ, Clarke JS (1983) Pharmacological action of breakdown products of atracurium and related substances. Br J Anaesth [Suppl] 55:11S–15SGoogle Scholar
  6. 6.
    Fahey MR, Morris RB, Miller RD et al (1981) Pharmacokinetics of Org NC 45 (Norcuron) in patients with and without renal failure. Br J Anaesth 53:1049–1053PubMedCrossRefGoogle Scholar
  7. 7.
    Foldes et al (1983) Br J Anaesth 55:97SPubMedCrossRefGoogle Scholar
  8. 8.
    Gramstad L, Lilleaasen P (1982) Dose-response relation for atracurium, Org NC 45 and pancuronium. Br J Anaesth 54:647–651PubMedCrossRefGoogle Scholar
  9. 9.
    Hughes R, Payne JP (1983) Clinical assessment of atracurium using the single twitch and tetanic responses of the adductor pollicis muscles. Br J Anaesth [Suppl] 55:47S–52SGoogle Scholar
  10. 10.
    Karpati E, Biro K (1980) Pharmacological study of a new competitive neuromuscular blocking steroid, pipecurium bromide. Arzneimittelforsch 30:346–354PubMedGoogle Scholar
  11. 11.
    Lienhart A, Desnault H, Guggiari M et al (1983) Vecuronium bromide: Dose response curve and haemodynamic effects in anaesthetised man. In: Agoston S (ed) Clinical experiences with norcuron. Excerpta Medica, Amsterdam (Excerpta Medica, Current Clinical Practice Series, vol 6, pp 46–53)Google Scholar
  12. 12.
    Marshall IG, Gibb AJ, Durant NN (1983) Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide (Org NC 45) and its potential metabolites in the anaesthetized cat. Br J Anaesth 55:703–714PubMedCrossRefGoogle Scholar
  13. 13.
    Merret RA, Thompson CW, Webb FW (1983) In vitro degradation of atracurium in human plasma. Br J Anaesth 55:61–66CrossRefGoogle Scholar
  14. 14.
    Newton DEF, Richardson FJ, Agoston S (1982) Preliminary studies in man with pipecuronium (arduan), a new steroid neuromuscular blocking agent. Br J Anaesth 54:789P–790PGoogle Scholar
  15. 15.
    Nightingale, Bush (1983) Br J Anaesth 55:115SPubMedGoogle Scholar
  16. 16.
    Philbin et al (1983) Br J Anaesth 55:131SPubMedCrossRefGoogle Scholar
  17. 17.
    Savage DS, Sleigh T, Carlyle J (1980) The emergence of Org NC 45, 1-[(2β, 3α, 5α, 16β, 17β)-3,17 bis (acetyloxy)-2-(lpiperidinyl)-adrostan-16-yl]-1-methylpiperidinium bromide, from the pancuronium series. Br J Anaesth [Suppl] 52:3S–9SCrossRefGoogle Scholar
  18. 18.
    Savarese JJ, Kitz RJ (1975) Does clinical anesthesia need new neuromuscular blocking agents? Anesthesiology 42:236–238PubMedCrossRefGoogle Scholar
  19. 19.
    Stanlake JB (1979) Ions-cyclic nucleotides-cholinergy. In: Stoclet JC (ed) Advances in pharmacology and therapeutics. Pergamon, Oxford New York, p 303Google Scholar
  20. 20.
    Twohig MM, Ward S, Corail IM (1983) Conditions for tracheal intubation using atracurium compared with pancuronium. Br J Anaesth [Suppl] 55:87S–89SGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • S. Agoston
  • J. Swen
  • F. J. Richardson
  • O. M. Rashkovsky
  • D. E. F. Newton
  • A. Bencini
  • J. M. Ket

There are no affiliations available

Personalised recommendations